bioRxivPharmacology & ToxicologyPreprint
Synthesis of substituted oxabicyclic phenol derivatives with increased affinity and activity for the classical estrogen receptor ERα
Richard A. PepermansiD, Antonio J. Tenorio, Travis Saxon, Marat R. TalipoviD, William A. MaioiD, Chinnasamy Ramesh, Eric R. ProssnitziD, Jeffrey B. ArterburniD
Abstract
The classical estrogen receptor (ER) is a steroid hormone receptor known for its role in both health and disease. ER, like its counterpart ER{beta}, acts as a receptor for its endogenous ligand 17{beta}-estradiol (E2) and is capable of binding a diverse set of natural and synthetic small molecules. Several screening campaigns have identified various ER ligands, based on the oxabicyclo[3.3.1]-nonene scaffold, that act as ER agonists. One such campaign extensively characterized an oxabicyclic ER agonist, termed AB-1. Herein, we report the synthesis of a series of analogs based on the scaffold of AB-1 (herein termed 1), focusing on the enhancement of their binding to ER and functional potencies in ER mediated assays. We identify a new substituted compound 9 that achieves subnanomolar potencies for ER binding (IC50= 0.45 nM) and ER dependent transcription (EC50= 0.37 nM) and proliferation (EC50= 0.03 nM), with potencies approaching those of E2. The high potency of 9 provides a promising scaffold for the potential development of new ER-targeted therapeutics.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Bisphenol A derivatives act as novel coactivator binding inhibitors for estrogen receptor β
M. Iwamoto, T. Masuya, … A. Matsushima·bioRxiv·May 10, 2021
- A new chemotype of chemically tractable nonsteroidal estrogens based on a thienopyrimidine core.
V. R. Sammeta, J. D. Norris, … T. M. Willson·bioRxiv·Apr 15, 2022
- Potent Estrogen Receptor β Agonists with Inhibitory Activity In Vitro, Fail to Suppress Xenografts of Endocrine-Resistant Cyclin-dependent Kinase 4/6 inhibitor-Resistant Breast Cancer Cells
L. M. Marcho, C. C. Coss, … M. A. Cherian·bioRxiv·Jan 12, 2024
- Dual mechanism estrogen receptor inhibitors
J. Min, J. C. Nwachukwu, … K. W. Nettles·bioRxiv·Jul 6, 2020
- An Innovative Non-Hormonal Strategy Targeting Redox Active Metals to Down-Regulate Estrogen-, Progesterone-, Androgen- and Prolactin-Receptors in Breast Cancer
F. Shehadeh-Tout, H. H. Milioli, … Z. Kovacevic·bioRxiv·Feb 2, 2023
- Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
J. Datta, N. Willingham, … M. A. Cherian·bioRxiv·Jan 14, 2022